ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We are dedicated to our patients and committed to delivering medications that meet unmet needs in the current therapeutic landscape.

Biopharmaceutical oral therapies autoimmune diseases inflammatory disorders orphan and rare diseases pancreatic cancer diabetic nephropathy ANCA-associated vasculitis atypical hemolytic uremic syndrome chemokine and chemoattractant receptors Focal Segmental Glomerulosclerosis oral therapeutics immuno-oncology Hidradenitis Suppurativa Chronic Kidney Disease Diabetic Nephropathy Pancreatic Cancer C3 Glomerulopathy Small Molecule Therapeutics Chemoattractant System Chemokine Drug Discovery Inflammatory Bowel Disease (IBD) Rheumatoid Arthritis (RA) Avacopan Complement Receptor ADVOCATE AURORA LUMINA B2B Biotech SaaS Commercial Physical Research Biotechnology Biotech Pharmaceuticals